Medical management of primary hyperparathyroidism
Arch. endocrinol. metab. (Online)
;
66(5): 689-693, Sept.-Oct. 2022. tab
Artículo
en Inglés
|
LILACS-Express
| LILACS
| ID: biblio-1420074
ABSTRACT
ABSTRACT Primary hyperparathyroidism (PHPT) is an endocrine disorder resulting from the hyperfunction of one or more parathyroid glands, with hypersecretion of parathyroid hormone (PTH). It can be managed by parathyroidectomy (PTX) or non-surgically. Medical therapy with pharmacological agents is an alternative for those patients with asymptomatic PHPT who meet guidelines for surgery but are unable or unwilling to undergo PTX. In this review, we focus upon these non-surgical aspects of PHPT management. We emphasize the most studied and widely used pharmacological alternatives bisphosphonates, denosumab, cinacalcet and hormone therapy, in addition to combined therapy. We also address the relevant aspects of perioperative management.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Tipo de estudio:
Guía de Práctica Clínica
Idioma:
Inglés
Revista:
Arch. endocrinol. metab. (Online)
Asunto de la revista:
Endocrinologia
/
Metabolismo
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
Brasil
/
Estados Unidos
Institución/País de afiliación:
Columbia University/US
/
Universidade de Pernambuco/BR
Similares
MEDLINE
...
LILACS
LIS